Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$68.06 USD

68.06
1,889,601

+0.13 (0.19%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $68.07 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (148 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Nalak Das headshot

Buy 5 Medical Instruments Stocks to Enhance Your Portfolio

by Nalak Das

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These stocks are: ALC, RXST, HOLX, VCYT, MASI.

Zacks Equity Research

Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know

by Zacks Equity Research

Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

Hologic (HOLX) Is Considered a Good Investment by Brokers: Is That True?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Hologic (HOLX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks Equity Research

HOLX vs. SONVY: Which Stock Is the Better Value Option?

by Zacks Equity Research

HOLX vs. SONVY: Which Stock Is the Better Value Option?

Zacks Equity Research

Is High Tide (HITI) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how High Tide Inc. (HITI) and Hologic (HOLX) have performed compared to their sector so far this year.

Zacks Equity Research

A Dive into Hologic (HOLX) International Revenue Trends and Forecasts

by Zacks Equity Research

Review Hologic's (HOLX) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Zacks Equity Research

Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock

by Zacks Equity Research

Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Equity Research

Hologic's (HOLX) Q2 Earnings Beat Estimates, 2024 View Up

by Zacks Equity Research

Hologic's (HOLX) GYN Surgical Q2 performance was driven by strong results from MyoSure and Fluent Fluid Management.

Zacks Equity Research

Hologic (HOLX) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Hologic (HOLX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Hologic (HOLX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of 6.19% and 1.69%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Will These 5 MedTech Stocks Beat Forecasts This Earnings Season?

by Urmimala Biswas

Here is a sneak peek into how the five MedTech stocks, HOLX, ZBH, ILMN, TFX and BRKR, are expected to fare in their quarterly results slated to be released tomorrow.

Riya Anand headshot

How You Should Play Hologic (HOLX) Ahead of Q2 Earnings

by Riya Anand

Hologic's (HOLX) second-quarter 2024 earnings will likely reflect gains from the GYN surgical business and the growing adoption of Panther instruments.

Zacks Equity Research

Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Stay Ahead of the Game With Hologic (HOLX) Q2 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Hologic (HOLX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.

Zacks Equity Research

The Zacks Analyst Blog Highlights 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp

by Zacks Equity Research

10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp are included in this Analyst Blog.

Urmimala Biswas headshot

3 Medical Products Stocks Set to Beat This Earnings Season

by Urmimala Biswas

Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.

Zacks Equity Research

Hologic (HOLX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Equity Research

Hologic (HOLX) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

Hologic (HOLX) reachead $75.36 at the closing of the latest trading day, reflecting a -0.03% change compared to its last close.

Zacks Equity Research

Hologic (HOLX) Q2 Earnings Might Rise on GYN Surgical Growth

by Zacks Equity Research

Hologic's (HOLX) second-quarter fiscal 2024 performance is likely to be driven by the GYN Surgical portfolio.

Zacks Equity Research

Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Molecular Diagnostics business and GYN Surgical is likely to have driven Hologic's (HOLX) fiscal second-quarter performance.

Zacks Equity Research

Hologic (HOLX) Increases Despite Market Slip: Here's What You Need to Know

by Zacks Equity Research

Hologic (HOLX) reachead $77.54 at the closing of the latest trading day, reflecting a +0.27% change compared to its last close.

Zacks Equity Research

Hologic's (HOLX) New Launches Aid, Macroeconomic Issues Ail

by Zacks Equity Research

Hologic's (HOLX) Breast Health segment is gaining from a broad portfolio of solutions for breast cancer care, primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment.

Zacks Equity Research

Hologic (HOLX) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

Hologic (HOLX) concluded the recent trading session at $77.38, signifying a -0.77% move from its prior day's close.